"...on June 6, 2011, we added Vandetanib to the list of Drugs with a Risk of Causing Torsades de Pointes. Keep in mind that whenever a drug is added to any of our lists, it is also automatically included on our list of Drugs to be Avoided by CLQTS (congenital Long QT Syndrome) Patients.
Vandetanib, which will be marketed under the brand name Zactima®, is an anti-cancer drug of the tyrosine kinase inhibitor class. It was approved in April 2011 for use in adults with medullary thyroid cancer for whom surgery is not an option."
Ref: 1. “FDA approves new treatment for rare form of thyroid cancer” Retrieved 6/14/2011